

## DETAILED ACTION

### Status of Action

Receipt of Amendments/Remarks filed on 04/06/2011 is acknowledged.

Receipt of certified copy of the English translation of French Application No. 03/00507 on 04/06/2011 is acknowledged. It has been considered and placed in the file.

### EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Kenneth Meyers on 05/06/2011.

- **Claim 1 at line 3 and claim 8 at line 2:** please amend 3-methoxy-PREG to 3 $\beta$ -methoxy-PREG.
- **Claim 1 at line 2:** please deletes the comma "," between the words patient and comprising.
- **Claim 3 is cancelled.**
- **Amendment to the originally filed specification (filed on 07/15/2005):**
  - Please amends 3-methoxy-PREG to 3 $\beta$ -methoxy-PREG at:

30  
Page 3: line ~~29, 30~~

Change(s) applied  
to document,

/A.S.A./  
7/8/2011

Please delete the paragraph at page 19, lines <sup>25-31</sup>~~23-31~~, of the specification and

insert the following replacement paragraph:

These mice express the longest human tau protein isoform. They present symptoms of neurological dysfunction expressed as muscular weakness and a reduction in motor coordination which correlate histologically with the appearance of abnormal ~~axons~~neurites and hyperphosphorylated tau proteins as is seen in Alzheimer's disease. This pathological phosphorylation decreases the affinity of tau for microtubules and favors its aggregation.

Please delete the paragraph at page 21, lines 18-21, of the specification and insert the following replacement paragraph:

These results obtained *in vitro* and *in vivo* clearly demonstrate that molecule 43B (3-methoxy-PREG) gives spectacular results on the growth of ~~axons~~neurites in culture and on the ~~medullary~~spinal cord compression model.

Please delete the paragraph at page 21, lines <sup>23-25</sup>~~24-25~~, of the specification and insert the following replacement paragraph:

**Example 10: Other molecules according to the invention**

The indices of ~~bending~~binding and activity are expressed as a percent of PREG.

Please delete the paragraph at page 21, lines 26-27, of the specification and insert the following replacement paragraph:

B*i*nding (affinity) is measured by the displacement of PREG-<sup>3</sup>H.

Please delete the paragraph at page 21, line 31 to page 22, line 2, of the specification and insert the following replacement paragraph: